FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2049752014> ?p ?o ?g. }

• W2049752014 endingPage "956" @default.
• W2049752014 startingPage "951" @default.
• W2049752014 abstract "<h3>ABSTRACT</h3> We tested a low-dose naltrexone and acetaminophen combination for episodic migraine prevention. We randomly assigned patients to naltrexone and acetaminophen combination (n=6) or placebo (n=6) for a 12-week double-blind treatment. Non-responders continued into open-label treatment with naltrexone and acetaminophen combination (n=5) for additional 12 weeks. Patients were adults who experienced 5 to 17 (average 9.7) migraine days at baseline. The primary endpoint was the mean change in the monthly migraine days during the last 4 weeks of the double-blind treatment period. The key secondary endpoint was the mean change in the monthly migraine days from the 4-week double-blind follow-up (2nd baseline) to the last 4 weeks of the open-label treatment period. The magnitude of the treatment effect for the naltrexone and acetaminophen combination observed in the double-blind period was 2.2 fewer monthly migraine days than placebo (p=0.43). Four out of 6 (66.7%) naltrexone and acetaminophen-treated patients experienced 75% reduction in migraine days compared to 1 out of 6 (16.7%) placebo-treated patients (p=0.09). In the open-label phase, treatment with the naltrexone and acetaminophen combination (n=5) led to 8.2 fewer mean monthly migraine days (from 11.8 to 3.6), representing 69.5% improvement (p=0.03), and 100% of the patients experienced a 50% reduction in monthly migraine days. Adverse events were mild to moderate and transient, included dry mouth, fatigue, sedation, nausea, and feeling jittery. We postulate that naltrexone’s toll-like receptor (TLR4) antagonism properties prevent pro-inflammatory cytokines’ production in the trigeminal ganglion averting “overactive nerves” (layman’s term) and migraine. Although this trial used low-dose naltrexone (defined as 1 – 5 mg/day), in future phase 3 studies we will test a range of naltrexone and acetaminophen combination doses." @default.
• W2049752014 created "2016-06-24" @default.
• W2049752014 creator A5035336455 @default.
• W2049752014 creator A5055149339 @default.
• W2049752014 creator A5071802203 @default.
• W2049752014 date "1987-09-01" @default.
• W2049752014 modified "2023-09-26" @default.
• W2049752014 title "Sudden infant death syndrome in south east Scotland." @default.
• W2049752014 cites W1509613230 @default.
• W2049752014 cites W1938227490 @default.
• W2049752014 cites W1975164676 @default.
• W2049752014 cites W2015603661 @default.
• W2049752014 cites W2021562301 @default.
• W2049752014 cites W2029236016 @default.
• W2049752014 cites W2034377706 @default.
• W2049752014 cites W2110378128 @default.
• W2049752014 cites W2124540084 @default.
• W2049752014 cites W2148684946 @default.
• W2049752014 cites W2286359587 @default.
• W2049752014 cites W1980579199 @default.
• W2049752014 doi "https://doi.org/10.1136/adc.62.9.951" @default.
• W2049752014 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1778600" @default.
• W2049752014 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/3674948" @default.
• W2049752014 hasPublicationYear "1987" @default.
• W2049752014 type Work @default.
• W2049752014 sameAs 2049752014 @default.
• W2049752014 citedByCount "8" @default.
• W2049752014 countsByYear W20497520142018 @default.
• W2049752014 crossrefType "journal-article" @default.
• W2049752014 hasAuthorship W2049752014A5035336455 @default.
• W2049752014 hasAuthorship W2049752014A5055149339 @default.
• W2049752014 hasAuthorship W2049752014A5071802203 @default.
• W2049752014 hasBestOaLocation W20497520141 @default.
• W2049752014 hasConcept C118552586 @default.
• W2049752014 hasConcept C120665830 @default.
• W2049752014 hasConcept C121332964 @default.
• W2049752014 hasConcept C144024400 @default.
• W2049752014 hasConcept C149923435 @default.
• W2049752014 hasConcept C187212893 @default.
• W2049752014 hasConcept C2908647359 @default.
• W2049752014 hasConcept C2987955292 @default.
• W2049752014 hasConcept C558461103 @default.
• W2049752014 hasConcept C61511704 @default.
• W2049752014 hasConcept C71924100 @default.
• W2049752014 hasConcept C99454951 @default.
• W2049752014 hasConceptScore W2049752014C118552586 @default.
• W2049752014 hasConceptScore W2049752014C120665830 @default.
• W2049752014 hasConceptScore W2049752014C121332964 @default.
• W2049752014 hasConceptScore W2049752014C144024400 @default.
• W2049752014 hasConceptScore W2049752014C149923435 @default.
• W2049752014 hasConceptScore W2049752014C187212893 @default.
• W2049752014 hasConceptScore W2049752014C2908647359 @default.
• W2049752014 hasConceptScore W2049752014C2987955292 @default.
• W2049752014 hasConceptScore W2049752014C558461103 @default.
• W2049752014 hasConceptScore W2049752014C61511704 @default.
• W2049752014 hasConceptScore W2049752014C71924100 @default.
• W2049752014 hasConceptScore W2049752014C99454951 @default.
• W2049752014 hasIssue "9" @default.
• W2049752014 hasLocation W20497520141 @default.
• W2049752014 hasLocation W20497520142 @default.
• W2049752014 hasLocation W20497520143 @default.
• W2049752014 hasLocation W20497520144 @default.
• W2049752014 hasOpenAccess W2049752014 @default.
• W2049752014 hasPrimaryLocation W20497520141 @default.
• W2049752014 hasRelatedWork W1632477623 @default.
• W2049752014 hasRelatedWork W1974042200 @default.
• W2049752014 hasRelatedWork W2048418690 @default.
• W2049752014 hasRelatedWork W2060138425 @default.
• W2049752014 hasRelatedWork W2075371677 @default.
• W2049752014 hasRelatedWork W2160780866 @default.
• W2049752014 hasRelatedWork W2345715974 @default.
• W2049752014 hasRelatedWork W2409957712 @default.
• W2049752014 hasRelatedWork W2911740078 @default.
• W2049752014 hasRelatedWork W3179572266 @default.
• W2049752014 hasVolume "62" @default.
• W2049752014 isParatext "false" @default.
• W2049752014 isRetracted "false" @default.
• W2049752014 magId "2049752014" @default.
• W2049752014 workType "article" @default.